期刊
BLOOD
卷 105, 期 5, 页码 2090-2092出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2004-09-3579
关键词
-
类别
资金
- NIAID NIH HHS [R01 AI056153, R21 AI49872] Funding Source: Medline
We developed an approach that increases CD4(+)CD25(+) regulatory T-cell potency by antigen-specifically redirecting them against pathologic T lymphocytes. The regulatory cells are transgenically modified with chimeric receptors that link antigen-major histocompatibility complex (MHC) extracellular and transmembrane domains with the cytoplasmic signaling tail of T-cell receptor (TCR-xi). The receptors' antigen-MHC recognizes the TCR of cognate T lymphocytes. Receptor engagement stimulates the receptor-modified T cell (RMTC) through the linked chain. CD4(+)CD25(+) RMTCs expressing a myelin basic protein (MBP) 89-101-IA(s)-xi receptor, unlike unmodified CD4(+)CD25(+) T cells or CD4(+)CD25(-) RMTCs, prevented and treated experimental allergic encephalomyelitis (EAE) induced with MBP89-101. The RMTCs were effective even after the autoreactive T-cell repertoire had diversified to include specificities not directly targeted by the chimeric receptor. Remissions were sustained and mortality was decreased from more than 50% to 0%. These results provide proof of principal for a novel approach to enforce the interaction of regulatory and pathologic T lymphocytes, thereby facilitating the treatment of autoimmune disease. (C) 2005 by The American Society of Hematology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据